Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CASP6 | P55212 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | GNG2 | P59768 | 4/20 | 0.34 |
| ▸ | GNB1 | P62873 | 4/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.33 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405485 | 0.81 | MEN1 (0.49) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL170998 | 0.79 | ALDH1A1 (0.39) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL27426620 | 0.78 | CASP6 (0.38) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL19357602 | 0.76 | PRKD3 (0.34) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL15528926 | 0.70 | MEN1 (0.68) | ALDH1A1CYP2C9CASP6MEN1KMT2A | |
| SCHEMBL10064554 | 0.69 | NT5E (0.47) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL21894602 | 0.69 | NT5E (0.65) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL28120681 | 0.69 | MEN1 (0.39) | ALDH1A1CYP2C9CYP2C19HSD17B10CASP6 | |
| SCHEMBL24438859 | 0.68 | NT5E (0.63) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL29495048 | 0.68 | NT5E (0.63) | NT5EALDH1A1CYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167536-A1 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE | Dako Denmark A/S (DK) | 2010-03-31 | — | — | EP | claimed |
| WO-2009003492-A1 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE | DAKO DENMARK A/S (DK) | 2009-01-08 | — | — | WO | claimed |
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | DAKO DENMARK APS (DK) | 2024-05-09 | — | — | US | disclosed |
| US-11668705-B2 | General detection and isolation of specific cells by binding of labeled molecules | IMMUDEX APS (DK) | 2023-06-06 | — | — | US | disclosed |
| US-11585806-B2 | General detection and isolation of specific cells by binding of labeled molecules | IMMUDEX APS (DK) | 2023-02-21 | — | — | US | disclosed |
| US-20220205984-A1 | General Detection and Isolation of Specific Cells by Binding of Labeled Molecules | HERLEV HOSPITAL (DK) | 2022-06-30 | — | — | US | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10611818-B2 | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190085048-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | AGILENT TECHNOLOGIES, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10030065-B2 | MHC multimers, methods for their generation, labeling and use | DAKO DENMARK A/S (DK) | 2018-07-24 | — | — | US | disclosed |
| US-20180180601-A1 | General Detection and Isolation of Specific Cells by Binding of Labeled Molecules | IMMUDEX APS (DK) | 2018-06-28 | — | — | US | disclosed |
| US-20110318380-A1 | MHC Multimers in Cancer Vaccines and Immune Monitoring | DAKO DENMARK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-20110236411-A1 | MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics | DAKO DENMARK A/S (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20100168390-A1 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE | DAKO DENMARK A/S (DK) | 2010-07-01 | — | — | US | disclosed |
| WO-2010037402-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | MICA, CD74, HLA-DRB1 | NT5E 1654/4885ALDH1A1 2776/4885CYP2C9 4644/4885 |
| US-20100168390-A1 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE | MICA, CD74, HLA-DRB1 | NT5E 1629/4885ALDH1A1 2771/4885CYP2C9 4597/4885 |
| US-10030065-B2 | MHC multimers, methods for their generation, labeling and use | MICA, CD74, HLA-DRB1 | NT5E 1359/4885ALDH1A1 4785/4885CYP2C9 4722/4885 |
| US-20190085048-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | MICA, CD74, HLA-DRB1 | NT5E 1654/4885ALDH1A1 2776/4885CYP2C9 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.